Dear Colleague: As an optometrist, you may see older patients who have geographic atrophy (GA) secondary to age-related macular degeneration (AMD). We wanted to let you know that these patients may be eligible to participate in the PARASOL research study of an investigational gene therapy. The primary objective of the PARASOL study is to evaluate the efficacy and safety of a one-time intravitreal injection of the investigational gene therapy when compared to a sham procedure in patients with GA secondary to AMD. This study is sponsored by Janssen Research & Development, LLC. Eligible patients will: Be 60 years of age or older Have been diagnosed with GA secondary to AMD in at least one eye Have a BCVA of 35 letters or better using the ETDRS chart (Snellen equivalent 20/200) in the affected eye Have not had a history of or presence of retinal disease other than GA in the affected eye (e.g., diabetic eye disease) Additional criteria will apply. Total study participation includes 18 study visits over the course of 19 months. If you have patients who are interested in learning more about this study, they may visit GeographicAtrophyResearch.com for more details. The site includes an educational video explaining the study, GA, and gene therapy. It also has a pre-screener assessment, which allows them to answer study eligibility questions. If your patients meet the initial eligibility requirements, they will be prompted to locate the study clinic nearest them by zip code and submit their contact information. The site staff will then contact them and set up a screening appointment to determine their study eligibility. To stop receiving these messages, you may unsubscribe by clicking the link at the bottom of this email. Please ensure all local policies on patient privacy, including, but not limited to, obtaining written consent as needed, are followed.   Thank you for your consideration of this important research. Sincerely, The PARASOL Study Team Privacy Policy | Legal Notice | Unsubscribe ©Janssen Research & Development, LLC 2023. All rights reserved. This email message is published by Janssen Research & Development, LLC, which is solely responsible for its content. This message is intended only for use by residents in the United States The image depicted contains models and is being used for illustrative purposes only. You are reminded of your and your employer’s obligation to adhere to all local privacy policies and state and federal regulations with respect to the protection and use of patients’ health information. This email was developed under the direction and sponsarship of QD Solutions, Inc.